Taconic Capital Advisors LP Acquires New Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Taconic Capital Advisors LP acquired a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the third quarter, HoldingsChannel reports. The institutional investor acquired 5,000 shares of the biotechnology company’s stock, valued at approximately $624,000. Sarepta Therapeutics makes up approximately 0.3% of Taconic Capital Advisors LP’s investment portfolio, making the stock its 15th largest holding.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Principal Financial Group Inc. boosted its stake in Sarepta Therapeutics by 693.7% during the 2nd quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock valued at $57,356,000 after purchasing an additional 317,277 shares during the last quarter. Rhumbline Advisers boosted its stake in Sarepta Therapeutics by 146.3% during the 2nd quarter. Rhumbline Advisers now owns 270,941 shares of the biotechnology company’s stock valued at $42,809,000 after purchasing an additional 160,942 shares during the last quarter. Blair William & Co. IL boosted its stake in Sarepta Therapeutics by 303.7% during the 2nd quarter. Blair William & Co. IL now owns 174,282 shares of the biotechnology company’s stock valued at $27,537,000 after purchasing an additional 131,112 shares during the last quarter. Summit Partners Public Asset Management LLC boosted its stake in shares of Sarepta Therapeutics by 547.9% in the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock worth $17,250,000 after buying an additional 116,800 shares during the last quarter. Finally, Retirement Systems of Alabama purchased a new position in shares of Sarepta Therapeutics in the 2nd quarter worth $18,433,000. Institutional investors own 86.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on SRPT shares. Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $152.00 to $167.00 in a research note on Thursday, November 7th. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Guggenheim upped their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Evercore ISI decreased their price objective on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. Finally, Piper Sandler reduced their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $175.77.

Sarepta Therapeutics Price Performance

NASDAQ SRPT opened at $137.94 on Friday. The firm has a market capitalization of $13.18 billion, a P/E ratio of 110.35 and a beta of 0.81. The firm’s fifty day simple moving average is $122.16 and its two-hundred day simple moving average is $131.43. Sarepta Therapeutics, Inc. has a 12-month low of $78.67 and a 12-month high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.